Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Stock Information for Nuwellis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nuwellis Inc.

Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings
Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.
Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum
Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian(TM) Pediatric System with Advanced Clamp Safety Technology
Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025
Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®
Nuwellis Receives New US Patent Reinforcing Vivian(TM) Pediatric Device Focused on Safer, More Precise Ultrafiltration
Nuwellis, Inc. Participates in a Virtual Investor "What This Means" Segment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.